US FDA accepts for review GSK’s NDA for linerixibat to treat cholestatic pruritus in patients with PBC: London, UK Tuesday, June 3, 2025, 11:00 Hrs [IST] GSK plc announced the U ...

Drugmaker GSK revealed on Monday that a new drug application for its linerixibat asset had been accepted for review by the US ...

We adapted our protocol for biliary cholesterol secretion with published methods for measuring transintestinal cholesterol elimination. Bile was diverted and biliary lipid secretion maintained by ...

This research article is published in the Case Reports in Clinical Radiology, published by Scientific Scholar.Neuroendocrine tumours (NETs) affecting the extrahepatic bile ducts are ...

More information: Vindhya Vijay et al, Generation of a biliary tract cancer cell line atlas identifies molecular subtypes and therapeutic targets, Cancer Discovery (2025). DOI: 10.1158/2159-8290 ...

GSK has shared promising results from a late-stage study of its investigational oral ileal bile acid transporter inhibitor linerixibat in patients with the rare autoimmune liver disease primary ...

July 07, 2004 Carolias Disease? Diagnostic choices in this case include melanoma and hepatoma.... CTisus, May 01, 2004 A 14-Year-Old Boy With Jaundice and Pruritus This patient presented to his ...

The VANTAGE study is evaluating volixibat in patients with cholestatic pruritus caused by primary biliary cholangitis (PBC). “The extended VANTAGE analysis provides encouraging insights into the ...

GSK plc announced positive results from the GLISTEN phase III trial evaluating linerixibat, an investigational targeted inhibitor of the ileal bile acid transporter (IBAT), in adults with cholestatic ...

Interim results from the ongoing Phase III ASSURE trial demonstrated that Livdelzi maintained a consistent biochemical response in patients with primary biliary cholangitis ... improvements in ...

Top-line results from the Phase III GLISTEN trial (NCT04950127) show that the novel therapy linerixibat produced a significant reduction in pruritus in adult patients with primary biliary cholangitis ...